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9ABSTRACT:
Breast cancer (BC) is the second most cause of death worldwide. In Italy
there are approximately 40,000 new cases per year and 11,000 deaths, representing
one of the major causes of morbidity and mortality cancer in females. In Tuscany it
has been estimated, in 2010 approximately 4100 breast cancer cases will be
diagnosed and 850 deaths. Many preclinical and clinical trials have been performed
to investigate and establish effective treatments.
HER2 receptor is overexpressed in 20–30 % of BC and it has been chosen to
be an effective therapeutic target. Trastuzumab (Herceptin), a humanized monoclonal
antibody, has been approved by FDA to be anti-HER2 therapy, but the mechanism
by which Trastuzumab exerts its antitumor activity is not fully understood.
Nevertheless, Trastuzumab has been suggested to induce antibody-dependent cellular
cytotoxicity (ADCC), inhibit HER2 extracellular domain cleavage, or inhibit PI3K/
AKT survival signalling, either by down-regulating HER2 signalling or by increasing
PTEN membrane localization and phosphatase activity, leading to a decline in
PI3K/AKT pathway activation and inhibition of proliferation. In spite of this, it is
still largely unclear why almost half of the breast cancer patients overexpressing
HER2 are initially do not respond to Trastuzumab based therapy even when
combined with chemotherapy, or eventually become resistant to Trastuzumab during
treatment. Mutational defects in HER2/PIK/AKT/PTEN signalling pathway and Fc-
-receptors polymorphisms have been suggested to be involved in Trastuzumab
resistance. In addition, activation of HER-related receptors, such as insulin-like
growth factor I receptor (IGF-R1) has been suggested in preclinical studies to
increase PI3K/AKT signalling pathway, resulting in limited Trastuzumab efficacy.
We proposed the involvement of PIK/AKTl/PTEN pathway and ADCC immune
response in the mechanism of Trastuzumab resistance. We collected 77 samples of
HER-2 positive metastatic breast cancer (MBC) patients. Mutational analysis have
been performed on hot spots exons 9 and 20 of PIK3CA, exon 4 of AKT1 and exons
5, 7 and 8 of PTEN genes. Furthermore, F158V and R131H polymorphisms of
FcγRIIIa and FcγRIIa genes have been performed. Our results showed a highly
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significant impact of PIK3CA/AKT1/PTEN pathway gaining mutation on overall
survival (OS) of the study population (P<0.0001) and a high significant relationship
between PIK3CA mutations and (PFS-I) (P=0.0001). Homozygous SNPs
V158V/H131H of FcγRIIIa and FcγRIIa are significantly related with better OS of
our study population (P=0.0037). In conclusion, our results suggest the important
role of PIK3CA gene mutation and FcγRIIIa polymorphisms in the patient’s OS,
which could be used as a molecular predicting marker for the Trastuzumab
resistance. Moreover, we found that IGF1-R expression is related with patient’s
response to Trastuzumab (p < 0.05).
An understanding of Trastuzumab resistance mechanisms would be a helpful
tool in the development of rational drug combinations to circumvent resistance and
allow better selection of patients likely to respond.
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OBJECTIVES:
This study aims to analyze some molecular determinants of resistance to
Trastuzumab “Herceptin” such mutations in PTEN, PI3K/Akt and HER2 genes,
overexpression of IGF-R1, and polymorphisms of FcγRIIIa and FcγRIIa following
Trastuzumab therapy, in order to find a predictive pattern of mutations,
polymorphisms and gene expression that is related with Trastuzumab resistance in
HER2 positive metastatic breast cancer patients. Formalin Fixed Paraffin Embedded
(FFPE) samples have been collected for 77 patients of HER2+ metastatic breast
cancer (MBC) treated with Trastuzumab. Obtained results have been correlated with
the clinical outcome of these patients. The gold standard will be the development of
clinical assay permitting accurate diagnosis of implicated resistance mechanism in
each subset of patients, which may help in the design of more efficient treatment
protocols.
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INTRODUCTION:
Breast cancer (BC) is the second most cause of death worldwide [1]. In Italy
there are approximately 40,000 new cases per year and around 11,000 deaths,
representing one of the major causes of morbidity and mortality cancer in females
[2]. In Tuscany it has been estimated, in 2010 approximately 4100 breast cancer
cases will be diagnosed and 850 deaths [3]. Many preclinical and clinical trials have
been performed to investigate and establish effective treatments [4, 5].
In the last four decades the development of new strategies to treat breast cancer
has been focused on designing of specific therapy for certain known signaling
molecules that are involved in signaling pathways of cell proliferation, migration and
angiogenesis. Understanding of regulation and expression mechanisms of cell
signaling is very helpful in the development of specific therapies for certain targets
[6]. Due to this fact, HER2 has been identified as a target in certain cancers. Her2
(erbB2/neu) gene encodes an epidermal growth factor receptor type 2 (EGFR2)
(ErbB2) or HER2 a tyrosine kinase receptor, HER2/neu gene located on
chromosome 17 (q21.1) (1, 21) (Figure. 1). HER2 cell surface protein has been
targeted in patients with metastatic breast cancer MBC, because it is significantly
overexpressed in about 20 – 30 % of invasive breast cancers [7-12]. HER2
overexpression has also been associated with aggressive tumor phenotype and
reduced survival rate [13]. Moreover, inappropriate activation of HER2 has been
associated with the development and severity of many cancers [14].
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Figure 1: Location of HER2/neu gene on chromosome 17. (A) Normal gene’s copy
number and estimated protein level of expression (B) amplified HER2/neu gene
copies and estimated protein expression level in HER2 positive breast cancer.
HER2 is a 185-kDa transmembrane oncoprotein (p185) (Figure. 2) [9]. Despites
mouse’s 44 KD ligand, human HER2 has no known stimulatory ligand, but there is a
suspicious 30 KD ligand [15].
Figure 2: HER-2 structure consists of 3 major regions, Tyrosine Kinase domain in
the intracellular side, membrane binding helix domain and the extracullar region
(ECD) which is consisting of 4 domains, I, II, III and IV.
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There are four known members in ErbB family of receptor tyrosine kinases
(RTKs), epidermal growth factor receptor (EGFR), ErbB2 (HER2), ErbB3 (HER3),
and ErbB4 (HER4). They are typical RTKs with an extracellular ligand binding
region, a single membrane-spanning region, and a cytoplasmic tyrosine kinase-
containing domain (Figure. 2). EGF-family peptides bind to ErbB receptors based on
their receptor specificity; these ligands have been divided into three major groups.
The first group includes epidermal growth factor (EGF), transforming growth factor
(TGF)-a, amphiregulin (AR), and epigen (EPG), which bind specifically to EGFR;
the second group includes betacellulin (BTC), heparin-binding EGF (HB-EGF), and
epiregulin (EPR), which exhibit dual specificity, binding both EGFR and ErbB4; and
the third group is neuregulins (NRGs), forms two subgroups on the basis of their
capacity to bind ErbB3 and ErbB4 (NRG-1 and NRG-2) or only ErbB4 (NRG-3 and
NRG-4) (Figure. 3) [16-18].
Figure 3: HER-2 is a member of 4 EGFR family of tyrosine kinase receptor; HER-2
has no known ligand while the other EGFRs have their specific ligands to be
activated. The four members share the same main structural features.
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ErbB2 (HER2) is activated via heterodimerization with the other ligand-bound
receptors (Figure. 4) [9, 16, 19].
Figure 4: Activation of ErbB receptors. Activation of ErbB receptors requires
homodimerization or heterodimerization with HER-2, this dimerization process
requires ligand binding to EGFR, ErbB3 and ErbB 4, on the other hand HER-2 does
not require ligand binding to dimerize with other EGFRs.
The most studied signaling pathways of HER2, involved the downstream
signaling of RAS/RAF/MAPK and/or PI3K/Akt cascades (Figure. 5) [6].
Dimerization of HER2 receptor leads to cross-phosphorylation of the C-terminal,
which starts activation of signaling process that involves two cascade pathways,
MAPK and PI3K-Akt pathway. MAPK pathway activation leads to transcription of
genes that drive cellular proliferation, migration, differentiation and angiogenesis.
On the other hand, PI3K-Akt pathway activation leads to cell survival and anti-
apoptosis signaling [20].
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Figure 5: Signal transduction by ErbB receptors. Activation of ErbB receptors by
dimerization induces signal transduction through two major pathways; PIK3CA
activation leads to further activation of downstream signaling involved in cell
survival, invasion, and metastasis and anti-apoptotic mechanism. An alternative
pathway involves activation of MAPK through RAS signaling, which leads to cell
division and Invasion.
The first line strategy against HER2 overexpressing tumors has been the
production of monoclonal antibodies (mAbs) targeting the extracullar domain.
Trastuzumab (Herceptin) a humanized monoclonal antibody has been approved by
FDA for the treatment of HER2 overexpressing breast cancer in adjuvant and
metastatic setting [7, 21, 22]. Unfortunately, a significant number of HER2
overexpressing breast cancer patients have been reported to develop resistance
against Trastuzumab or they may have initial resistance for Trastuzumab therapy [6,
23].
Currently, the optimal duration of Herceptin treatment is unknown. In most
patients who initially respond to Herceptin, disease progression begins again within a
year. A clearer understanding of the mechanisms that contribute to Herceptin
resistance is needed to increase the magnitude and duration of response [13].
Despites the discovery of Domain IV as a Trastuzumab binding site (Figure. 6) [24-
26], the exact mechanism of Herceptin action is not fully understood.
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Figure 6: The structure of human sHER2 and Herceptin-Fab. Ribbon diagram of the
human sHER2 and Herceptin Fab complex showing binding site on domain IV [26].
Nevertheless, different mechanisms of Herceptin action have been proposed:
Such as internalization and degradation of HER-2, disruption of receptors
dimerization, disruption of downstream signaling pathways (Figure. 7), G1 arrest
and reduction of proliferation, induction of p27kip1-cdk2 complex formation and
apoptosis, inhibition of Akt activity and suppression of angiogenesis because it has
been noticed that there is a reduction of tumor vasculature in vivo and reduction of
expression of pro-angiogenic VEGF, TGF-a, Ang-1, PAI-1, induction of anti-
angiogenic TSP-1, ADCC immune-mediated responses through stimulation of
natural killer cells (Figure. 8), inhibition of HER-2 ECD proteolysis and inhibition
of DNA repair [13].
18
Figure 7: Trastuzumab binding and dimerization. Trastuzumab binding is proposed
to inhibit the cleavage of HER-2 and prevents dimerization with other EGFR
receptors; it has been proposed that the expression of truncated HER-2 (p95) mimics
the binding site of Trastuzumab antibody. Proteolytic inhibition by Trastuzumab has
been proposed as a mechanism of anti-tumor action.
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Figure 8: Trastuzumab action and ADCC action. Trastuzumab action could involve
activation of ADCC immune response, two mechanisms could be involved in
Trastuzumab action, ADCC and releasing of interferons from cytotoxic cells to kill
tumor cells, on the other hand prevention of dimerization has also been proposed.
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Since the pharmacokinetics of Trastuzumab is not fully understood, many
mechanisms of Trastuzumab resistance have been proposed [6, 27-29].
Preclinical studies have proposed some mechanisms of Trastuzumab resistance
I. Obstacles for Trastuzumab binding to HER2, altered receptor–
antibody interaction or steric-hindrance of receptor-antibody
interaction
II. Up-regulation of HER2 downstream signaling pathways.
III. Signaling through alternate pathways and compensatory signaling
from other HER receptors
IV. Failure to trigger immune-mediated mechanisms to destroy tumor
cells.
V. Mutated receptor; low HER-2 level increased cell signaling.
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I. Obstacles for Trastuzumab binding to HER2:
A constitutively active, truncated form of HER2 receptor, p95HER2, has
kinase activity but lacks the extracellular domain and the binding site of
Trastuzumab (Figure. 9). In-vitro data have suggested Trastuzumab could block
p185HER2 cleavage and consequent production of constitutively active p95HER2, a
truncated form of complete HER2 receptor [30]. A retrospective study has revealed a
strong association between the presence of p95HER2 and clinical resistance to
Trastuzumab treatment [31]. In that study, sensitivity to Trastuzumab has been
evaluated according to p95HER2 expression measured by immunofluorescence in 46
patients with metastatic breast cancer. Only 1 out of 9 patients (11.1%) expressing
p95HER2 responded to Trastuzumab, whereas 19 of the 37 patients (51.4%) with
tumors expressing p185HER2 achieved clinical response.
Three models have been suggested to explain p95HER2 production: Protease-
mediated generation of p95HER2 [32-34], alternative initiation of translation [35],
and alternative mRNA splicing [36-38].
Specific proteases have been found to be involved in HER2 shedding. HER2
shedding has been attributed to various zinc-containing metalloproteases including
members of the ADAM (A Disintegrin and Metalloproteases) and MMP (Matrix
Metallo Proteases) families [39].
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Figure 9: Proposed mechanisms of Trastuzumab resistance: A) Truncated HER-2
oncoprotein prevents Trastuzumab binding, B) Mutations in the PIK/AKT signalling
pathway interferes with the action of Trastuzumab, C) Activation of alternative
pathway of IGF1-R playing a role in Trastuzumab resistance
Alternative splicing may also produce HER2 ECD. At least two distinct
truncated HER2 ECD proteins are encoded by alternative splicing of the HER2
transcript. A 2.3 kb mRNA variant encodes an intracellular 100 kDa protein (stay
inside the cell) which is composed of the first 633 amino acids and contains almost
the entire HER2 ECD (ECD sub-domains I–IV) [40].
Another HER2 mRNA splicing variant has been identified to encode a soluble
truncated 68 kDa sHER2 (also called Herstatin) that includes the first 340 amino
acids of HER2 with two ECD sub-domains (I and II) and ends with a unique
carboxyl tail sequence at the place of the ECD sub-domain III [41].
Most studies have suggested elevated sHER2 is associated with worse
outcome of breast cancer, and it has become clear that HER2 expression in breast
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cancer alone does not adequately predict response to HER2-targeted therapy [42].
The recently developed assay to measure sHER2 has been suggested to be used in
combination with IHC or FISH to optimize the identification of patients with HER2
over-expression or amplification [40].
Epitope masking has also been investigated as a mechanism of resistance to
Trastuzumab. Mucin 4 (MUC4) is large, highly O-glycosylated membrane-
associated glycoprotein [43], which may interfere with Trastuzumab binding to
HER2. In a preclinical model using the human HER2 positive, JIMT-1 cell line
showed resistance to Trastuzumab, it has been observed that MUC4 was associated
with Trastuzumab epitope masking and decreased antibody-binding capacity [44]. In
that model, JIMT-1 resistance to Trastuzumab could be reversed by MUC4
knockdown. Moreover, CD44 and hyaluronan may also hinder the access of
Trastuzumab to HER2 receptor by masking its cognate epitope, and lead to treatment
resistance. It has been shown that treating JIMT-1 cells with an inhibitor of the
hyaluronan synthesis significantly reduces the hyaluronan levels leading to increased
binding of Trastuzumab to HER2 and its subsequent anti-tumoral effects [45].
II. Upregulation of HER2 downstream signaling pathways:
Loss of PTEN function caused by mutation of PTEN itself, or by
transcriptional regulation, has been described in several tumors and in up to 50% of
breast cancers [46]. PTEN normally inhibits the activation of PI3K. Therefore PTEN
loss results in the constitutive upregulation of PI3K/Akt (Figure. 9) [47]. HER2-
overexpressing metastatic breast cancer patients with deficient PTEN had
significantly poorer responses to Trastuzumab-based therapy than those with tumors
expressing normal PTEN [48, 49].
Phosphatase and tensin homolog (PTEN) has been suggested as a key
modulator of Trastuzumab sensitivity in HER2-overexpressing breast cancer because
PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K)
(Figure. 4). PTEN activation has been found to contribute to Trastuzumab antitumor
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activity. For instance, Trastuzumab treatment quickly increases PTEN membrane
localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via
Src inhibition. Moreover, reducing PTEN in breast cancer cells by antisense
oligonucleotides conferred Trastuzumab resistance in vitro and in vivo. Moreover,
patients with PTEN-deficient breast cancers have shown shorter survival time than
the normal PTEN patients [50, 51].
Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases that
regulate signaling pathways involved in cell proliferation, adhesion, survival and
motility. The PI3K pathway is considered to play an important role in tumorigenesis.
Activating mutations of the p110α subunit of PI3K (PIK3CA) have been identified in
a broad spectrum of tumors. Analyses of PIK3CA mutations reveals that they
increase the PI3K signal, stimulate downstream Akt signaling, promote growth
factor-independent growth and increase cell invasion and metastasis [52].
A large-scale RNA interference screening to discover genes involved in
Trastuzumab resistance in breast cancer identified only PTEN as a modulator of drug
sensitivity. Furthermore, oncogenic mutants of PIK3CA have also conferred
resistance to Trastuzumab in cell culture. In a cohort of 55 breast cancer patients,
activation of the PI3K pathway, as judged by the presence of oncogenic PIK3CA
mutations or low PTEN expression, has been associated with poor prognosis after
Trastuzumab therapy. Combined analysis of PTEN and PIK3CA identified twice as
many patients at increased risk for progression compared to PTEN alone [53].
Furthermore, Trastuzumab and Lapatinib have been evaluated in a panel of 18
HER2-amplified cell lines, using both two- and three-dimensional culture. Increased
phosphorylation of HER2, epidermal growth factor receptor (EGFR), HER3, and
insulin-like growth factor IR have been correlated with response to Lapatinib but not
Trastuzumab. Loss of PTEN or the presence of activating mutations in PI3K marked
resistance to Trastuzumab, but Lapatinib response was independent of these factors.
Concluding, increased activation of the PI3K/AKT pathway correlated with
resistance to Trastuzumab, which can be overcome by Lapatinib [54].
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PI3K mutations have also been implicated in Trastuzumab resistance through
PI3K/Akt pathway activation. PIK3R1 gene encodes the PI3K regulatory subunit
p85α; PIK3R1 mutations affect p85 function and induce constitutive activation of the
PI3K/Akt pathway [55, 56]. In addition, PIK3CA encodes the catalytic subunit of
p100α of PI3K, is also frequently mutated or overexpressed in human cancer [57].
Berns and colleagues have described a significantly improved ability to detect
patients with low response to Trastuzumab in a cohort of 55 patients with breast
cancer when combining the analysis of low PTEN expression and the presence of
oncogenic PIK3CA mutations [53]. Another study has described PIK3CA mutations
occur more frequently in elder patients for HER2-positive breast cancer, and
suggested PI3K pathway activation resulting from PTEN loss or PIK3CA mutations
may lead to drug resistance to Lapatinib and Trastuzumab [58].
Moreover, patients with PIK3CA mutations or increased PI3K pathway
activity had a significantly poorer survival despite adequate treatment with adjuvant
chemotherapy and Trastuzumab [59]. Microarray analysis has shown the
downregulation of PKA-RIIα regulatory subunit, conferred partial Trastuzumab
resistance in Her2-positive BT474 and SK-Br-3 cell lines. Forskolin activation of
PKA also produced significant protection against Trastuzumab-mediated Akt de-
phosphorylation [60].
III. Signaling through multiple alternate pathways:
Signaling through alternative pathways has been linked to Trastuzumab
resistance in various preclinical models. Clinical information confirming the
importance of most of the identified pathways is needed. For instance, Insulin-like
growth factor-I receptor, IGF-1R, another transmembrane TK receptor which
stimulates cell proliferation has been found to interact with HER2 in Trastuzumab-
resistant cell lines, inducing its phosphorylation (Figure. 9). In those preclinical
models, anti-IGF-IR drugs have restored sensitivity to Trastuzumab-resistant cell
lines [61]. IGF1R levels have been significantly increased in the Trastuzumab-
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resistant model, SKBR3/Tr, compared to the parental SKBR3 cell line. In both,
SKBR3/Tr and BT474/Tr cell lines, inhibition of IGF1R expression by siRNA or
inhibition of tyrosine kinase activity by NVP-AEW541 significantly increased
response to Trastuzumab. The dual targeting approach also improved response in the
parental SKBR3 cells but not in the BT474 parental cells [62].
Moreover, Trastuzumab has inhibited the growth of MCF-7/HER2-18 cells, a
HER2/neu and IGF-I receptors (IGF-IRs) overexpressing cells, only when IGF-IR
signaling was minimized by reducing fetal bovine serum (F-BSA). In SKBR3 cells, a
HER2/neu receptor overexpressing cells with few IGF-IRs, Trastuzumab reduced
proliferation by 42% regardless of IGF-I concentration. Furthermore, Trastuzumab
effect has been reverted in SKBR3 cells when IGFIRs overexpressed and cultured
with IGF-I [63].
C-Met receptor is frequently co-expressed with HER2 in some cancer cell
lines, and it has been suggested to contribute to Trastuzumab resistance through
sustained Akt activation. HER2-overexpressing breast cancer cells respond to
Trastuzumab with a rapid upregulation of c-Met receptor expression, and c-Met
activation protects cells against Trastuzumab while the loss of c-Met function
produced through RNA interference improves the response of these cell lines to
Trastuzumab [64]. Moreover, it has been suggested that Met activation protects cells
against Trastuzumab by abrogating p27 induction [64].
Moreover, the role of Met receptor in TKI resistance has also been described
in NSCLC, Gefitinib-resistant NSCLC cell lines display MET gene amplification and
Met receptor appears to couple to the PI3K pathway via ErbB3[65].
IV. Failure to trigger immune-mediated mechanisms to destroy tumor cells:
Antibody-Dependant Cell-Mediated Cytotoxicity ADCC immune response
has been suggested to be involved in Trastuzumab action (Figure. 8). Trastuzumab
has been found to be involved in induction of ADCC response in HER-2-amplified
HCC1954 and SKBR3 cell lines, and in all five of the non-amplified cell lines, which
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had low levels of detectable HER-2 (CAL-51, CAMA-1, MCF-7, T47D, and
EFM19). On the other hand, Trastuzumab did not induce ADCC in the K562 control
cell line or MDA-MB-468, which have very low levels of HER-2.
Fcγ receptors have different affinity to antibody types, which suggests their
role in Trastuzumab efficacy. Genomic polymorphism that produces Valine (V) or
Phenylalanine (F) phenotypes at position 158 of FcγRIIIa has been suggested to
influence Trastuzumab affinity to the Fcγ receptor (Figure. 10) [66]. Immune
effector cells carrying the FcγRIIIa V/V alleles mediate ADCC of Trastuzumab
better than cells bearing the F allele [67]. In the clinic, FcγRIIIa 158V/F
polymorphism significantly impairs clinical response rates and progression-free
survival (PFS) of patients treated with Trastuzumab in the metastatic setting [68].
Moreover, Fifty-four consecutive patients with HER-2/neu–amplified breast cancer
receiving Trastuzumab plus Taxane for metastatic disease have been evaluated for
FcγRIIIa-158 Valine/Phenylalanine (V/F), FcγRIIa-131 Histidine/Arginine (H/R),
and FcγRIIb-232 Isoleucine/Threonine (I/T) polymorphisms. Strong impact of
FcγRIIIa-158 on anticancer treatment has been proposed [69, 70].
Figure 10: Antibody dependant cytotoxic cell ADCC and involvement of Fc
receptors in Trastuzumab action. Under the presence of low affinity Fc receptors to
Trastuzumab, the efficacy of Trastuzumab is proposed to be reduced in this group of
HER2+ MBC patients.
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On the other hand, FcγRIIIa and FcγRIIa genotyping has been performed for
1,286 of non-metastatic HER2 positive patients who are enrolled in a trial of
adjuvant Trastuzumab-based chemotherapy. No correlation has been found between
(Disease Free Survival) DFS and FcγRIIIa/FcγRIIa polymorphisms in Trastuzumab-
treated patients [71].
Other proposed mechanisms for Trastuzumab resistance:
Recently, other mechanisms of Trastuzumab resistance have been proposed to
reduce the efficacy. Cell cycle controlling proteins and mRNA have been described
in some recent works to be involved in Trastuzumab action.
i. Cyclin E
Cyclin E overexpression has been related with Trastuzumab resistance in both
in vivo and in vitro. In a cohort study of 34 HER2+ patients treated with
Trastuzumab-based therapy, cyclin E amplification/overexpression has been
associated to worse clinical benefit (33.3% compared with 87.5%, P < 0.02) and
lower progression-free survival (6 mo vs. 14 mo, P < 0.002) compared to cyclin E
non-overexpressing tumors. Moreover, inhibition of cyclin E activity in cyclin E-
amplified Trastuzumab resistant clones, either by knockdown of cyclin E expression
or treatment with cyclin-dependent kinase 2 (CDK2) inhibitors, led to a dramatic
decrease in proliferation and enhanced apoptosis. Suggesting treatment with CDK2
inhibitors may be a valid strategy in patients with breast tumors with HER2 and
cyclin E co-amplification/overexpression [72].
ii. miRNA
miR-21 expression and function has been upregulated and elevated in HER2
BT474, SKBR3, and MDA-MB-453 breast cancer cells that are induced to acquire
Trastuzumab resistance by long-term exposure to the antibody, whereas protein
expression of the PTEN gene, a miR-21 target, has been reduced. Blocking of miR-
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21 action re-sensitized the resistant cells to the therapeutic activities of Trastuzumab.
Moreover, ectopic expression of miR-21 in HER2 breast cancer cells confers
resistance to Trastuzumab. In vivo, administering miR-21 antisense oligonucleotides
restored Trastuzumab sensitivity in the resistant breast cancer xenografts by inducing
PTEN expression, whereas injection of miR-21 mimics conferred Trastuzumab
resistant in the sensitive breast tumors via PTEN silence. Up-regulation of miR-21 in
tumor biopsies obtained from patients receiving pre-operative Trastuzumab therapy
has been associated to poor Trastuzumab response [73].
In another study, micro-RNA profiling analysis has been conducted to screen
micro-RNAs that were up- or down-regulated in HER2-positive cells lines only.
miR-26a and miR-30b have been identified as a Trastuzumab-inducible micro-
RNAs. Transfecting miR-26a and miR-30b induced cell growth suppression in the
BC cells. Using the prediction algorithms for micro-RNA targets, cyclin E2
(CCNE2) has been identified as a target gene of miR-30b [74].
iii. IFNs
It has been reported that anti–ErbB-2 mAb therapy is dependent on the
release of IFN-I and II but is independent of perforin or FasL, excluding the
importance of the classical antibody-dependent lymphocyte-mediated cellular
cytotoxicity. It has been demonstrated that anti–ErbB-2 mAb therapy of experimental
tumors derived from MMTV-ErbB- 2 transgenic mice triggers MyD88-dependent
signaling and primes IFN-γ–producing CD8+ T-cells and independent of IL-1R or
IL-17Ra signaling. Moreover, it has been demonstrated that anti–PD-1 or anti-
CD137 mAb significantly improve the therapeutic activity of anti–ErbB-2 mAb in
immunocompetent mice [75].
Most of Trastuzumab resistance mechanisms have been identified in preclinical
models and have not yet been validated in clinical samples. One important goal of
this study is to determine which mechanism/s is/are clinically relevant to
Trastuzumab resistance in HER2+ metastatic breast cancer patients.
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Herceptin (Trastuzumab) Side Effects;
In spite of the therapeutic benefits of Trastuzumab (Trz), cardiotoxic side
effects are still an issue. This effect is potentiated particularly when Trz is
administered following Doxorubicin (DOX) treatment. Among the various
mechanisms that may account for DOX and Trz-induced cardiotoxicity, the role of
oxidative stress has gained significant support. The adjuvant use of Trz can
potentiate cardiomyocyte damage through a ‘dual-hit’ mechanism, which includes
inhibition of the neuregulin-1 survival signaling pathway and angiotensin II-induced
activation of NADPH oxidase, with the ability to further increase reactive oxygen
species production (ROS). Preventive therapies for DOX- and Trz-induced cardiac
dysfunction have eluded investigators, but may include the prophylactic use of
angiotensin-converting enzyme inhibitors, beta-blockers and use of antioxidants.
Thus, a better understanding of the mechanisms leading to this characteristic drug-
induced cardiomyopathy, as well as potential cardio-protective strategies is required
[76].
The most common adverse reactions are fever, nausea, vomiting, diarrhea,
infections, cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and
myalgia. Serious infusion reactions (angioedema, anaphylaxis) and pulmonary
toxicity (pneumonitis, acute respiratory distress syndrome) have also been reported
within 24 hours of administration [77, 78].
Economic and Clinical Issues
The average wholesale price for Trastuzumab is $2930 for 440 mg. For 70
kg, each 2 mg/kg dose would cost approximately $1000, and a yearly regimen would
cost $50,000. About 5–10 women per 100,000 population have metastatic breast
cancer, between 90 and 100 per 100,000 have localized breast cancer, and around 40
per 100,000 have regional breast cancer [79].
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Thus, with a US female population of 143,000,000 approximately 7,000–
14,000 women have metastatic breast cancer, 130,000– 140,000 have localized
breast cancer, and 60,000 have regional breast cancer. If Trastuzumab is to be a
standard part of the adjuvant regimen for HER2-positive patients, the cost of treating
this population could increase by almost $1 billion for Trastuzumab alone. There
would also be additional cost for treating heart failure associated with administration
of the medication [23].
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Materials and Methods:
Specimen collection: 77 formalin fixed paraffin embedded (FFPE) tumor
samples have been collected from HER2+ patients treated with Trastuzumab for
metastatic breast cancer (MBC) disease since 2003 at the Pathology and Medical
Oncology Department of the Az-USL5 of Pisa and the Hospital-University of Pisa
(Appendix A). HER2 scoring has been evaluated according to the standard protocols
at the Pathology and Medical Oncology Department. All patients have been
diagnosed as 3 + by IHC assay, moreover, 2 + patients have been confirmed by FISH
assay to be HER2 +. The average age at diagnosis of our study group is 55 years, 45
% of the patients are less than 55 years old. Patients have been classified clinically
into four major groups according to their response to Trastuzumab. CR: complete
response, PR: partial response, SD: stable disease and PD: progressive disease.
DNA extraction and evaluation: DNA and RNA extraction from FFPE
tissues has been performed on 3 to 4 sections of 10 m thickness. Each paraffin
block has been sectioned under sterile conditions. De-waxing has been performed by
adding 1 mL of Xylene, incubated for 5 min at 40 o C, centrifuged at maximum
speed, de-waxing has been repeated 3 times. Xylene cleaning has been performed by
adding 1 mL absolute ethanol, centrifuged at maximum speed; ethanol washing has
been repeated 3 times. All samples have been subjected to air dry for 30-60 minutes
under the chemical hood.
DNA Extraction: To extract DNA from dried sections we used an automated
system (Helix Extraction System, Diatech) and a commercial kit (Helix DNA Plus,
Diatech) according the manufacturer’s instructions.
Manual DNA extraction has been performed by using commercial kit from
Qiagen (QIAamp DNA FFPE Tissue Kit). Briefly, 180 µl Buffer ATL has been
added to dried pellet, followed by adding 20 µl of proteinase K, mixed and incubated
overnight at 56 o C. 200 µl AL Buffer added to the sample, and mixed thoroughly by
vortex, Then 200 µl of ethanol (96–100%) have been added, and mixed again
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thoroughly by vortex. 1.5 ml tube centrifuged to remove drops from the inside of the
lid. Carefully the entire lysates have been transferred into the QIAamp MinElute
column (in a 2 ml collection tube), and centrifuged at 6000 x g (8000 rpm) for 1 min.
QIAamp MinElute column has been placed in a clean 2 ml collection tube, collection
tube containing the flow-through has been discarded. 500 µl of Buffer AW1 added to
QIAamp MinElute column, centrifuged at 6000 x g (8000 rpm) for 1 min, then the
collection tube containing the flow-through discarded. 500 µl of Buffer AW2 has
been added and centrifuge at 6000 x g (8000 rpm) for 1 min, then collection tube
containing the flow-through has been discarded. Centrifugation at full speed (20,000
x g; 14,000 rpm) has been performed for 2 min to dry the membrane completely.
QIAamp MinElute column was placed in a clean 1.5 ml micro-centrifuge tube and 50
µl Buffer ATE has been added to the center of the membrane and incubated at room
temperature (15–25°C) for 1 min, followed  by centrifugation at full speed (20,000 x
g; 14,000 rpm) for 1 min. The quantity/quality of extracted DNA has been estimated
by Nanodrop 1000 spectrophotometer by using 1 μl of undiluted DNA solution.
RNA Extraction: RNA have been extracted by using (Helix Extraction
System, Diatech) and commercial kit (Helix RNA Plus, Diatech) according the
manufacturer’s instructions.
cDNA synthesis: By using (Thermo Scientific RevertAid First Strand cDNA
Synthesis Kit, #K1621), 0.5-1µg of RNA have been added into sterile nuclease-free
tube on ice, 1µl random hexamer primers has been added and completed to total
volume 12µl by adding nuclease-free water, then incubated at 65o C for 5 min.
Following reagents have been added as the indicated order: 4µl of 5x reaction buffer,
1 µl of RiboLock 10 RNase inhibitor (20u/ µl), 2 µl of mM dNTP mix, 1 µl of Revert
AID M-MuLV reverse transcriptase (200u/ µl) to reach 20 uL total volume, mixed
gently and centrifuged, then incubated for 5 min at 25o C, followed by 60 minutes at
42o C, the reaction terminated by heating at 70o C for 5 minutes. The synthesized
cDNA used immediately or stored at -20o C for less than a week. For longer storage
cDNA samples have been stored at -80o C.
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Primers and PCR: All primers have been designed by using Primer3
software and verified by BLAST on Pubmed database for mismatching. PCR
reactions for all target sequences has been performed under the following conditions:
in 30 µl reaction volume containing 75 mM Tris–HCl, 1.5 mM MgCl2, 50 mM KCl,
20 mM (NH4)2SO4, 0.2 mM of each primer and 1 U of Taq DNA polymerase. PCRs
have been done under the following cycling conditions: an initial 7 min of
denaturation at 95 Co followed by 45 cycles for 45 sec each at 94 Co, appropriate
annealing temp (Table. 1), extension at 72 Co for 1 min and a single final extension
step for 10 min at 72 Co.
PCR Reaction cleanup: PCR reaction cleanup has been performed by using
Montage PCR filter system (MultiScreen PCR96 Filter Plate) from Millipore. PCR
amplified products have been mixed with pure water (30 ul of PCR reaction + 80 uL
of pure water) and loaded to 96 wells plate, vacuum aspiration has been applied for
5-10 minutes until wells are dry, washing with pure water has been applied for 3
times (100), final step was performed by adding 40 uL of pure water and agitated for
10 min at 40 rpm and transferred to new clean tubes, purified PCR product used
immediately for sequencing reaction or stored at 4o C.
DNA sequencing: Direct DNA sequencing has been performed by using Big
Dye Terminator (Ver. 3.1) kit (Applied Biosystems, USA) according to the
manufacturer’s instructions. To prepare the reaction mixtures, 4 uL of Terminator
Ready Reaction Mix has been mixed with 2 uL Big Dye Sequencing Buffer and 4-6
uL of purified PCR product, 3.2 pmol of primers, up to 20 uL of de-ionized water,
mixed and spin. Cycling PCR has been performed under the following conditions (30
cycles for 10 sec at 95 o C, 5 sec at 50 o C and 3 min at 72 o C).
Sequencing Reaction Cleanup: Sequencing reaction cleanup has been
performed by using Montage and MultiScreen Sequencing Reaction Cleanup system
(Montage SEQ96 Sequencing Reaction Cleanup Kit). PCR Sequencing reaction have
been mixed with pure water (20 ul of PCR reaction + 80 uL of pure water) and
loaded to 96 wells plate, vacuum aspiration has been applied for 5-10 minutes until
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wells are dry, washing with pure water has been applied for 3 times (100), final step
was performed by adding 25 uL of pure water and agitated for 10 min at 40 rpm and
transferred to new clean tubes and stored at 4o C until applied for sequencing.
Sequencing has been performed by ABI Prism Genetic Analyzer system
3130xl (Applied Biosystems, USA). 8 uL of cleaned sequence reaction product has
been mixed with 8 uL of formaldehyde, mixed, denatured at 95o C for 5 min and
applied for direct sequencing.
Mutational analyses on HER-2, PTEN, PIK3CA and AKT1 genes;
Polymorphism of FcγRIIa: The mutational analysis of HER-2 (exons 17-21),
PTEN (exons 5, 7 and 8), PIK3CA (exons 9 and 20) and Akt1 (exon 4) genes and
FcγRIIa polymorphisms have been performed on DNA by PCR amplification
followed by cycling PCR. Cycling PCR product cleaned by Millipore cleaning 96
wells plate according to the manufacturer’s instructions, then sequenced by ABI
PRISM 3130XL Genetic Analyzer (Applied Biosystems, USA).
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Gene Exon Primer Annealing Co
Size
(bp)
HER-2
17
5’-CTAGCCCTCAATCCCTGACC-3’
5’-GGCTGGGAGGACTTCACC-3’
58 203
18
F-5’-GAGGCGGGGTGAAGTCCT-3’
R-5’GGCCCTGACCTTGTAGACTG-3’
58 210
19
F-5’-CCCACGCTCTTCTCACTCAT-3’
R-5’-AGAGACCAGAGCCCAGACCT-3’
58 212
20
F-5’-CTCTCAGCGTACCCTTGTCC-3’
R-5’-AGGTGCATACCTTGGCAATC-3’
58 220
21
F-5’-GACTCTTGCTGGGCATGTG-3’
R-5’-TTCTCCCATGGGCTAGACAC-3’
58 287
PIK3CA
9
F-5’- CTG TGA ATC CAG AGG GGA AA-3’
R-5’- CCA CAA ATA TCA ATT TAC AAC
CAT TG -3’
58 450
20
F-5’-GCTGAGGTGACCCTTGTCTC-3’
R-5’-ACAGCTTGCAAGGACTCTGG-3’
58 421
Akt1 4
F-5’-GGTAGAGTGTGCGTGGCTCT-3’
R-5’-CAAATCTGAATCCCGAGAGG-3’
58 205
PTEN 5
F-5’-TTCTGAGGTTATCTTTTTACCACA-3’
R-5’-TAGGGCCTCTTGTGCCTTTA-3’
58 308
7
F-5’-AAAATCGTTTTTGACAGTTTGACA-3’
R-5’-TTCATTGGGAGAAATATCCAAAA-3’
58 278
8
F-5’-TGTTTAACATAGGTGACAGATTTTCT-
3’
R-5’-TGGCTTTGTCTTTATTTGCTTT-3’
57 420
9
F-5’-CAGTAGAGGAGCCGTCAAAT-3’
R-5’-CTGGATCAGAGTCAGTGGTG-3’
58 437
FcγRIIIa 158
Sequence to analyze:
A/CAAGCCCCCTGCAGAAGTAGGAGCCG
F-5’- GTTCAAGGAGGAAGACCCTATTCA-3’
R- 5’- AGTGATGGTGATGTTCACAGTCTC-3’
S – 5’- ACACATTTTTACTCCCAA – 3’
58 16
FcγRIIa 131
F-5’- AAGGACAAGCCTCTGGTCAA-3’
R- 5’-TCTTGGCAGACTCCCCATAC-3’
58 201
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Table 1. Sets of Primers that are used for PCR amplification of specific genes, each
set is combined with specific annealing temperature and expected product size.
qPCR : GoTaq® qPCR Master Mix kit from Promega has been used to
perform qPCR. Total volume of 25 uL contained 12.5 master mix, 0.2 uM of
primers, upto100 ng DNA template and nuclease free water. qPCR setting was: hot-
start activation at 95°C for 2 minutes, 40 X of denaturation at 95°C for 15 seconds
annealing/extension 60°C for 60 seconds and final step of dissociation at 95°C.
qPCR and HRM have been carried out by using (Rotor-Gene Q, QIAGEN).
Pyro-sequencing: PyroMark Q96 ID has been used to analyse FcγRIIIa
polymorphisms, while the primers for this analysis have been designed by PyroMark
Assay Design SW 2.0.
Data analysis: Statistical analyses have been carried out by specific computer
program (GraphPad /Prism 4). All tumour samples have been provided with detailed
clinical data which allowed us to perform an association study between genes
mutations and patients’ survival and treatment responses by using statistical analysis
such as Pearson χ2 test or two-tailed t-test and Kaplan Meier survival analyses.
IGF1R
cDN
A
F-5’- CTC CTG TTT CTC TCC GCC G -3’
R- 5’- ATA GTC GTT GCG GAT GTC GAT -3’
60 150
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Results:
HER2 Mutational Analysis:
77 samples have been subjected to DNA sequencing of the hot spots of exons
17, 18, 19, 20 and 21 of HER2 gene. None of the analyzed samples showed any
mutation on the screened exons 17, 18, 19, 20 and 21. Interestingly, exon 17 of HER-
2 gene showed a polymorphism Ile625Val (Ile625Val) (Figure. 11), which is not
related with the overall survival OS or progression free survival PFS-I of the patients
(Figure. 12).
Figure 11: Histogram of HER2-exon 17.  Ile625Val (Ile655Val) polymorphism
shows change in the codon sequence from ATC to GTC. Upper histogram represents
wild type codon and polymorphic codon in the lower histogram sequence.
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Figure 12: Ile625Val polymorphism and survival. Kaplan Meier curve represents
Ile625Val polymorphism on exon 17 of HER-2/neu gene do not show any
significance with patients survival (Blue line 1: Ile655Ile) (Red line2: Ile625Val).
PIK3CA mutational analysis:
We performed DNA sequencing of our 77 samples by using ABI Prism
Genetic Analyzer system 3130xl; our results showed PIK3CA is frequently mutated
in HER-2 positive metastatic breast cancer patients. Screening of hot spot exons 9
and 20 of PIK3CA gene revealed various point mutations (Table. 2). Sixteen
samples have shown mutations in PIK3CA gene representing 21 % of our study
group. Seven mutations have been found on exon 9, while nine mutations have been
located on exon 20, representing 9 % and 12 % of PIK3CA mutations in the whole
study population and 44% and 56% of total PIK3CA mutations, respectively. We
reported E545K as the most frequent point mutation in our study population; five
samples showed E545K mutations representing 7 % of the whole study population
and 31% of total PIK3CA mutations. None of the patients has dual mutations in both
exons and all mutations have been reported previously (Appendix A and B).
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RESPONSE PIK9 PIK20
PD WT W1057X
PD H554R WT
PD WT D1018N
RC POST-CH WT H1047R
RM E542K WT
RP WT H1047R
RP WT H1047L
RP E542K WT
RP E545K WT
RP N515S WT
RP WT M1010I
RP WT D1056N
SD WT H1047R
SD E545K WT
SD WT M1004I
NA E545K Wt
Table 2. Mutations of exons 9 and 20 of PIK3CA gene, 7 mutations were found on
exon 9 while exon 20 showed 9 mutations, detailed sequences of these mutations are
in the Appendix. PD: progressive disease, RP: partial response, SD: stable disease,
RM: medium response, RC: complete response.
STATGRAPHIC software has been used to perform survival analysis of our
study. Kaplan-Meier survival analysis have shown a highly significant reduction in
patients overall survival (OS) by gaining PIK3CA mutation (P < 0.0001) (Figure.
13). Moreover, progression free survival (PFS-I) has also been significantly reduced
by gaining PIK3CA mutations (P = 0.0001) (Figure. 14). In conclusion, gaining
PIK3CA mutations have shown a negative impact on the survival of HER-2 positive
metastatic breast cancer patients who are treated with Trastuzumab.
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Figure 13: PIK3CA/Akt1 mutations and Overall survival (OS). Kaplan Meier curve
shows Overall survival (OS) is significantly reduced by the presence of
PIK3CA/AKT1 mutations, P < 0.0001 (--------- PIK3CA/Akt1 mutated patients)
( Wt patients).
Figure 14: PIK3CA/AKT1 mutations and Progression free survival –I. Kaplan Meier
curve shows Progression free survival -I (PFS-I) is significantly reduced in the
presence of PIK3CA/AKT1 mutations, P = 0.0001 (--------- PIK3CA/Akt1 mutated
patients) ( Wt patients).
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Moreover, one of our major aims is to establish a relationship between
gaining PIK3CA mutations and Trastuzumab response, in order to use this
information to predict patient’s response before starting treatment.  In our study,
PIK3CA mutations have shown a difference between the progressive group (PD) and
the other groups (RP: partial response, SD: stable disease, RC: complete response) of
drug response. Our study group has only 7 patients with (PD) but contains the
highest percentage of PIK3CA mutations (43 %). On the other hand, the complete
response (RC) group has the lowest percentage of PIK3CA mutations (8 %) (Figure.
15).
Figure15: Percentage of PIK3CA mutations in each group of the patients. PD:
progressive disease group showed the highest percentage of PIK3CA mutations. PD:
progressive disease, RP: partial response, SD: stable disease, RC: complete response.
Akt1 mutations:
Akt1 has shown a very low incidence of mutations on exon 4 in our patients.
We reported 2 mutations in 77 patients, representing 2.6 % of the study population.
Up to our information; these mutations have not been reported previously (Table. 3).
Furthermore, we reported 5 silent mutations on exon 4 of Akt1 gene (Table. 3). Due
two low mutation numbers in this gene it is not possible to build Kaplan-Meier curve
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for survival analysis, so they have been included in the PIK3CA mutations analysis;
totally, PIK3CA and AKT1 mutations have the same impact on the patient’s survival
(Appendix A).
RESPONSE Akt1
NV L28F,T34T
PD Y38Y
RC 15522C/T
RC V57V
RC L28L,V45V
RP T34T
SD R23Q
Table 3. Mutations of exon 4 of Akt1 gene. Two missense mutations were found on
exon 4 while 5 silent mutations have been reported in our population, one mutation
has been found in the non-coding region at position 15522C/T. PD: progressive
disease, RP: partial response, SD: stable disease, RM: medium response, RC:
complete response
PTEN mutations:
We performed mutational analysis on hot spot exons 5, 7 and 8 of PTEN
gene. Fourteen samples have shown mutations on the mentioned exons representing
18 % of the study population distributed as the following: 7 (10.2 %), 9 (13.2 %) and
2 (2.9 %) on exons 5, 7 and 8, respectively. Five patients have shown more than one
mutation representing 7 % of the whole study population and 36 % of total PTEN
mutations (Table. 4) (Appendix A).
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Kaplan-Meier Survival analysis didn’t show statistical significant difference
by gaining PTEN mutations (Figure. 16), but the whole mutations in PIK3CA, AKT
and PTEN have shown a significant effect of these mutations on the OS (P= 0.009)
(Figure. 17) but not on the PFS-I (P > 0.05) (Figure. 18).
RESPONSE PTEN
PD V217I
PD V133I
RC G132D,V216M
RC Q110X
RC C105Y
RM Y225C
RP P96L, R233*
RP P213S,R233*
RP R130*, G230E
SD Q214*
SD C105Y
SD H272R
SD S227F, E291K
SD M134I
Table 4. PTEN gene mutations. 14 mutations have been found on exons 5, 7 and 8.
PD: progressive disease, RP: partial response, SD: stable disease, RM: medium
response, RC: complete response.
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Figure 16: PTEN mutations and Overall survival. Kaplan Meier curve of PTEN
mutations do not show any significant relationship with the OS of the study
population (P > 0.05).
Figure 17: PIK3CA/AKT1/PTEN mutations and Overall survival. Kaplan Meier
curve shows that Overall survival (OS) is significantly reduced in the presence of
PIK3CA/AKT1/PTEN mutations, P = 0.009 (--------- PIK3CA/AKT1/PTEN mutated
patients) ( Wt patients).
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Figure 18: PIK3CA/AKT1/PTEN mutations and PFS-I. Kaplan Meier curve of PFS-
I do not show significant relationship with gaining PIK3CA/AKT1/PTEN mutations,
P>0.05 (--------- PIK3CA/AKT1/PTEN mutated patients) ( Wt patients).
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FcγRIIa R131H polymorphism:
R131H polymorphism of FcγRIIa gene has been performed by direct
sequencing. Our results have shown the following distribution of the three
genotypes: 4 (5 %) patients have H131H, 57 (74 %) patients have R131H and 16 (21
%) patients have R131R polymorphisms (Appendix A) (Figure. 19). Due to the low
number of H131H polymorphism in our population we included this polymorphism
in the FcγRIIIa F158V survival analysis. Our data shows that H131H and/or V158V
homozygous genotypes are significantly related with the OS but not to the PFS-I
(Figure. 22).
Figure19: Genotypic distribution of H131H, H131R and R131R polymorphisms of
FcγRIIa. H131H homozygous genotype has the lowest percentage in our study
population.
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FcγRIIIa F158V polymorphism:
By using Pyro-sequencing and High Resolution Melting Point (HRM)-PCR
technologies (Figure. 21) we found the following results: 2 (3 %) patients have
F158F, 50 (65 %) patients have F158V and 25 (32 %) patients have V158V
polymorphisms on FcγRIIIa gene (Figure. 20).
Figure 20: Phenotypic distribution of V158V, F158V and F158F polymorphisms of
FcγRIIIa. F158F homozygous polymorphism has the lowest percentage in our study
population.
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(A)
(B)
(C)
50
(D)
(E)
(F)
Figure 21: Pyro-sequencing and HRM results of FcγRIIIa. (A) A/A homozygous
genotype, expressing F/F phenotype, (B) A/C heterozygous genotype, expressing
F/V phenotype, (C) C/C homozygous genotype, expressing V/V phenotype. E, F and
G representing the HRM results of FcγRIIIa polymorphisms.
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Kaplan-Meier survival analyses of FcγRIIa and FcγRIIIa polymorphisms
have shown a significant relationship with the patient’s overall survival OS (Figure.
22) but not to the PFS-I. Patients with V/V and H/H homozygous genotype have
shown better survival than other polymorphisms. Our results show a strong impact of
V/V and H/H on the patient’s survival.
Figure 22: FcγRIIIa and FcγRIIa polymorphisms and Overall survival. Kaplan
Meier curve shows that Overall survival (OS) is significantly improved in patients
with V/V and H/H homozygous polymorphisms of FcγRIIIa and FcγRIIa genes P =
0.0037 (Line 1: V/V or H/H patients) (Line 2: --------- F/R carrier patients).
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Figure 23: FcγRIIIa and FcγRIIa polymorphisms and Progression free survival.
Kaplan Meier curve of Progression free survival (PFS-1) is not significantly related
with V/V and H/H homozygous polymorphisms of FcγRIIIa and FcγRIIa genes P <
0.05 (Line 1: V/V or H/H patients) (Line 2: --------- F/R carrier patients).
Impact of all mutations and polymorphisms on the OS and PFS-I:
To determine the possible interacting role of all mutations and
polymorphisms together to predict or affect the OS or PFS-I of HER+ metastatic
breast cancer patients under the treatment of Trastuzumab, we performed Cox-
Proportional Hazard Regression analysis for PK3CA, AKT1, and PTEN mutations,
Cox-regression analyses have shown a highly significant impact of all these factors P
= 0.0009 (Figure. 24).
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Figure 24: PIK3CA/AKT1/PTEN mutations and Cox-Proportional Hazard
Regression of OS. Cox-Proportional Hazard Regression analysis of OS is
significantly related with the presence of PIK3CA/AKT1/PTEN mutations P <
0.0001 (--------- PIK3CA/Akt1 mutated patients) ( Wt patients).
In order to understand the impact of each combination of mutations and
polymorphisms factors we divided our groups in to 4 groups according to their
genotypes, (Wt and V/V or H/H patients), (Wt and F or R carrier patients),
(PIK3CA/AKT1/PTEN mutated and V/V and H/H SNPs) and
(PIK3CA/AKT1/PTEN mutated and F or R SNPs carrier patients).
Interestingly, we found that wild type patients (who have no mutation on the
screened hot spots) with homozygous V/V or H/H genotypes have much more butter
survival than the other genotypes
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Figure 25: PIK3CA/AKT1/PTEN mutations and FcγRIIIa and FcγRIIa SNPs and
Overall survival. Kaplan Meier curve shows that Overall survival (OS) is
significantly related with the presence of PIK3CA/AKT1/PTEN mutations and SNPs
of FcγRIIIa and FcγRIIa P = 0.0069, (1. Wt and V/V or H/H patients) (2.
Wt and F or R patients) (3.---------- PIK3CA/AKT1/PTEN mutated and
V/V and H/H SNPs) (4.---------- PIK3CA/AKT1/PTEN mutated and F or R SNPs
carrier patients).
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Figure 26: PIK3CA/AKT1/PTEN mutations and FcγRIIIa and FcγRIIa SNPs and
Progression free survival. Kaplan Meier curve shows that Progression free survival
(PFS-I) is not significantly related with the presence of PIK3CA/AKT1/PTEN
mutations and SNPs of FcγRIIIa and FcγRIIa, but PIK3CA/AKT1/PTEN mutations
and F or R SNPs carrier patients showing worse PFS-I. (1. Wt and V/V or
H/H patients) (2. Wt and F or R patients) (3.----------
PIK3CA/AKT1/PTEN mutated and V/V and H/H SNPs) (4.----------
PIK3CA/AKT1/PTEN mutated and F or R SNPs carrier patients).
Moreover; patients with any PIK3CA/Akt1 mutation and F or R genotypes
have worse survival than the other genotypes (Figure. 25). PFS-I did not show a
significant impact on patients survival, nevertheless, patients with any PIK3CA/Akt1
mutation and F or R genotypes still show the worse survival (Figure. 26).
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IGF1-R Expression Analysis:
In the last step of our research, we have investigated the proposed effect of
IGF1-R expression on the trastuzumab resistance. We performed Q-PCR by using
relative gene expression IGF1-R/B2M. Our results have shown IGF1-R expression
might be related with Trastuzumab response in HER-2 positive metastatic breast
cancer patients (Figure. 27); we found that IGF1-R is overexpressed in the three
groups of progressive disease (PD), partial response (RP) and stable disease (SD).
On the other hand, IGF1-R is significantly less expressed in complete response group
(RC) p < 0.05. These results might be very important tool for patients’ classification
prior starting treatment.
Figure 27: IGF1-R expression in HER-2 positive metastatic breast cancer patients.
Our data shows that complete response (RC) to Trastuzumab patients are the least
expressing of IGF1=R, * p < 0.05. (RC: complete response, PD: progressive disease,
RP: partial response, SD: stable disease).
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Discussion:
HER2 is significantly overexpressed in about 20 – 30 % of invasive breast
cancers [7-10]. In September 1998 Trastuzumab (Herceptin) became the second
monoclonal antibody approved for the treatment of a malignant condition, and the
first antibody approved for the treatment of a solid tumor. It is a mouse-human
chimeric antibody that produces anti-tumor effects by blocking the HER2-neu
receptor, and can also interact with human immune cells to affect antibody dependent
cell-mediated cytotoxicity ADCC. Nevertheless, the exact mechanism of
Trastuzumab mechanism of action is not fully understood. Pivotal trials in breast
cancer have shown that it has activity as a single agent in a subset of patients whose
tumors greatly overexpressed HER2, but results were even more impressive when it
was used in combination with chemotherapy [80, 81].
It has been proposed that Trastuzumab cannot block ligand-induced HER2
heterodimers, suggesting it cannot effectively inhibit HER2 signaling and high levels
of HER2 homodimers correlated with longer time to progression following
Trastuzumab therapy in a cohort of patients with HER2-overexpressing breast
cancer. Concluding, high levels of HER2 homodimers may predict a positive
response to Trastuzumab.
Unfortunately, almost 50 % of treated patients show resistance to
Trastuzumab at the beginning of regimen or eventually. Preclinical studies have
proposed some mechanisms of Trastuzumab resistance in HER2 positive breast
cancer patients. Mainly, obstacles for trastuzumab binding to HER2, upregulation of
HER2 downstream signaling pathways, signaling through alternate pathways and
failure to trigger immune-mediated mechanisms to destroy tumor cells [6, 27].
It has been demonstrated that Trastuzumab resistance mechanisms are related
with deregulation of PTEN/PI3K/Akt/mTOR pathway, and/or EGFR and IGF1R
overexpression in a subset of HER2-positive breast carcinomas [82]. Moreover, it
has been indicated that restoration of HER2-ECD expression sensitizes HER2-
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negative or HER2-downregulated human cancer cells to Trastuzumab-mediated
ADCC [83].
In spite of the involvement of HER family proteins in PTEN/PI3K/Akt
signaling pathway, we proposed mutations of HER2, PTEN, PI3K and Akt signaling
proteins, and IGF1R overexpression in a subset of HER2-positive breast carcinomas
to be contributed in the resistance of Trastuzumab. Moreover, ADCC is an immune
response to the presence of antibody binding to certain targets such as Trastuzumab
and HER2 complex; we proposed the impact of certain Fc receptors polymorphisms
to affect the efficacy of Trastuzumab.
Our study populations consists of 77 patients who have been diagnosed with
HER2 positive metastatic breast cancer according to the standard protocols of the
Pathology and Medical Oncology Department of the Az-USL5 of Pisa at Hospital-
University of Pisa.
We performed direct DNA sequencing for the main hot spots of PIK3CA,
Akt1, PTEN and HER2 genes, as well as screening of FcγRIIIa-158 and FcγRIIa-131
polymorphisms. Then, we performed analysis of patients’ survival in relation to
either gaining mutations or changing in FcγR polymorphisms. Our results show
consistent results with some preclinical and cohort clinical studies, proposing a
powerful role of these findings in predicting patient's response to Trastuzumab
treatment. Moreover, these results could be used in the development of new
therapeutic strategy for HER2 positive metastatic breast cancer patients.
PIK3CA is one of the most common mutated genes in various types of
cancers. In breast cancer, PIK3CA mutation has been estimated to be between 20%
and 40% [84]. Previously, our lab reported 35%-50% PIK3CA mutations in certain
population of breast cancer [85]. PIK3CA mutations have been independently
associated with poor prognosis of breast cancer patients [86]. Here we confirmed the
presence of similar incidence of PIK3CA mutations in an Italian population
diagnosed with HER2 positive metastatic breast cancer patients. 21% of the study
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population shows mutations in exon 9 and 20 of PIK3CA gene which is consistent
with national and international findings. We found E545K missense mutation in 5
samples of our patients. As expected, we found a strong relationship between
patient's overall survival (p < 0.0001) and progression free survival (p = 0.0001) and
gaining PIK3CA mutations. PIK3CA mutations showed a strong impact on patient's
survival, therefore we calculated the percentage of PIK3CA mutations in each subset
of HER2 positive patients. Complete response (RC) patients to Trastuzumab have
shown the least percentage of PIK3CA mutations (42 %); only one patient has
mutation out of 17. PIK3CA mutations show an independent risk factor of
developing resistance to Trastuzumab, suggesting the use of anti PIK3CA treatments
in combination with Trastuzumab.
Akt1 as a PIK3CA downstream signaling molecule is frequently mutated in
some cancers; we reported a very low percentage of Akt1 mutations on exon 4. Two
samples show two novel missense mutations on exon 4. Since mutation frequency of
Akt1 is very low in our population we included these two mutations in PIK3CA
mutation group to perform survival analysis. Our results show the same impact of
PIK3Ca/Akt1 mutations on patient's survival. Interestingly, we reported five silent
mutations on exon 4 of Akt1 gene, more studies are recommended to analyze Akt1
mutations in HER2 positive metastatic breast cancer patients.
PTEN is frequently mutated in breast cancer. PTEN, phosphatase tensin like
protein, is activated through cell signaling to inhibit activated PIK3CA by
dephosphorylation. Loss of PTEN has been correlated to Trastuzumab resistance
independently or in combination with other signaling molecules including PIK3CA
mutations. Here we proposed PTEN mutations to be involved In Trastuzumab
resistance; therefore we screened three hot spot exons 5, 7 and 8. As expected, we
reported 14 samples with PTEN mutations representing 18 % of our patients, but not
significantly related to patient's survival, concluding a low impact of gaining PTEN
mutation on predicting patient's response to Trastuzumab. Further studies are
recommended to screen PTEN mutations on all exons and there functional role of
these mutations, as well as PTEN-LOH analysis is highly recommended in such
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population. Our results present new data of PTEN mutations frequency in an Italian
population diagnosed with HER2 positive metastatic breast cancer.
We proposed HER2 mutation analysis as a factor that could be involved in
Trastuzumab resistance; therefore we screened hot spot exons by direct DNA
sequencing. Our results did not show any mutation in screened exons 17-21. We
found frequent presence of polymorphism on exon 17 (Ile625Val or Ile655Val)
(rs 1136201), but not related to patient's survival.
ADCC has been demonstrated to be a major mechanism of Trastuzumab
action, therefore FcγR polymorphisms have been proposed to play a role in
Trastuzumab resistance in some patients. Here we performed pyro-sequencing of
FcγRIIIa-158 polymorphisms, a highly specific and quick technique allowed us to
perform analysis with high throughout in a short period of time. Our results show a
highly significant impact of FcγRIIIa polymorphism on patients’ response to
Trastuzumab treatment. Overall survival shows an improvement in patients survival
when they have homozygous V158V (rs 396991) of FcγRIIIa or H131H
(rs 1801274) of FcγRIIa. On the other hand the other polymorphisms reduce patients’
survival, significantly. Preclinical studies demonstrated the major role of FcγR
polymorphisms on Trastuzumab mechanism against HER2 positive cells. Here we
confirmed the impact of FcγR polymorphisms on Trastuzumab response in HER2
positive metastatic breast cancer patients.
Obviously, our data show a strong impact of each factor on patients’ survival,
independently. Therefore, we decided to generate classes of patients according to
their PIK3CA, PTEN, Akt1 mutational status and FcγR polymorphisms. According
to these criteria we generated 4 groups: Wt and V/V or H/H patients, Wt and F or R
carrier patients, PIK3CA/AKT1/PTEN mutated and V/V and H/H SNPs patients, and
PIK3CA/AKT1/PTEN mutated and F or R SNPs carrier patients. Our results show an
interesting relationship between each group of patients and overall survival, for
instance, wt and V/V or H/H genotype shows strong improvement in patients’
survival. On the other hand worse outcome has been found in PIK3CA/AKT1/PTEN
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mutated and F or R SNPs carrier patients. These results suggest the possible
combination of molecular factors could be interacted to evaluate patient’s response to
Trastuzumab.
Alternative signaling pathway activation has been suggested to be contributed
in Trastuzumab resistance. IGF1R is involved in activation cell proliferation and cell
division, therefore, IGF1R overexpression has been considered as a player in
Trastuzumab response. We performed Q-PCR assay to quantify IGF1R expression in
our population, then IGF1R expression has been calculated in each subset of our
patients. Interestingly, we found significant reduction in IGF1R expression in
complete response (RC) patients; on the other hand IGF1R is overexpressed in all
other subsets of patients. Here we suggest IGF1R expression assay to be considered
in HER2 positive metastatic breast cancer patients, in order to predict the possible
classification of treated patients. Moreover, IGF1R expression assay is recommended
to be performed on larger group of HER2 positive patients.
Novel therapeutic strategies to circumvent Trastuzumab resistance have been
warranted, and agents targeting the HER, vascular endothelial growth factor, heat
shock protein 90, phosphoinositide 3 kinase/Akt/mammalian targets of rapamycin,
and insulin-like growth factor-1 receptor pathways represent rational approaches in
the management of HER2-positive disease [87].
Meanwhile, anti-VEGF strategies, such as bevacizumab, have demonstrated
promising activity and phase-III results are eagerly awaited. Other investigational
agents in HER2-positive MBC, including hsp90 and mTOR inhibitors, utilize novel
approaches to combat Trastuzumab resistance and have also shown promising
activity in early-phase clinical trials. IGF-1R inhibition is supported by biologic
rationale in the setting of Trastuzumab resistance due to receptor crosstalk, but
mature clinical data are lacking. The two antibody-based HER2-directed approaches,
pertuzumab and T-DM1, have shown promising efficacy [87].
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Moreover, KPL-4 and JIMT-1 Trastuzumab-resistant breast cancer cells have
been used to evaluate the combination IMO plus Trastuzumab as a therapeutic option
for Trastuzumab-resistant breast cancers. It has been shown that a cooperative effect
of IMO plus Trastuzumab in Trastuzumab resistant breast cancers due to IMO direct
antitumor and anti-angiogenic activity and antibody-dependent cell-mediated
cytotoxicity enhancement. Moreover, it has been suggested that toll-like receptor
9/HER interaction at membrane level as novel mechanism of action [88]. New
therapies include tyrosine kinase inhibitors, antibody–chemotherapy conjugates,
heat-shock protein inhibitors and antibodies that interfere with the formation of
ERBB2–ERBB3 dimers.
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Figure 28. Potential ERBB2 targets for anticancer therapy. Current approaches to
inhibit signaling through ERBB2 include antibody binding and inhibition of tyrosine
kinase activity. a. The antibody trastuzumab binds directly to domain IV of the
extracellular region of ERBB2, suppressing ERBB2 signaling activity, preventing
cleavage of extracellular domain and marking tumor cells that overexpressing
ERBB2 for further immunological attack through antibody-dependant cell-mediated
cytotoxicity. b. Pertuzumab, another ERBB2-specific monoclonal antibody, binds to
domain II of the extracellular region of ERBB2. As this region contains the
dimerization domain, pertuzumab binding prevents ERBB2 from forming dimers
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with its signaling partners- a key step in ERBB2- mediated signaling. c. The antibody
– drug conjugate trastuzumab- DM1 consists of trastuzumab conjugated to the anti-
microtubule agent DM1 (a maytansine derivative). After binding to ERBB2,
trastuzumab-DM1 is internalized and DM1 is released into the cell to exert its
cytotoxic effects. d. ERBB2-specific binding by antibodies with bispecific or
trispecific selectivity for cytotoxic effector cells can mark tumor cells that
overexpress ERBB2 for immunological destruction. e. Inhibition of the activity of
the ERBB2 tyrosine kinase domain with agents such a Lapatinib also prevents
ERBB2-dependent signaling. a. Heat shock protein 90 (HSP90) controls the stability
of the nascent and mature forms of ERBB2 and several downstream signaling
components, including RAF1 and AKT1. Inhibition of HSP90 activity results in
ubiquitylation and proteasomal degradation of both ERBB2 and its downstream
signaling partners, thereby abrogating the activity of the relevant signaling pathway.
[20]
It has been found that Trastuzumab inhibits glycolysis via downregulation of
heat shock factor 1 (HSF1) and lactate dehydrogenase A (LDH-A) in ErbB2-positive
cancer cells, resulting in tumor growth inhibition. Moreover, it has been found that
combining Trastuzumab with glycolysis inhibition synergistically inhibited
Trastuzumab-sensitive and –resistant breast cancers in vitro and in vivo [89].
Recent neoadjuvant studies have examined the effects of adding single or
dual agents targeting HER2 to chemotherapy, finding unanimously that dual HER2
targeting markedly improves pathologic response. These findings have significant
implications for future trial designs, particularly if the impact on pathologic response
is accompanied by improved disease-free survival or overall survival [90]. By
maximally blocking the HER family of proteins with therapeutic combinations, we
may move one step closer to durable control of ERBB2-amplified breast cancer [91].
Screening of CTC in Trastuzumab resistant BC patients and molecular
analysis of HER-2 and p95HER may help in the understanding of resistance
mechanism and prediction of the BC metastasis process. Recent studies tried to find
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tumor markers through the investigation of circulating tumor cells CTC. Some of
these studies found significant relationship between certain gene panels and the
prognoses of cancer [92]. It will be helpful to find some prediction markers such
p95HER2, loss and /or mutation of PTEN or PI3K and HER2 mutations in CTC [93-
96]. Alteration of HER2 status is very interesting issue during Trastuzumab
treatment, it was reported that HER2 amplification is reduced in vitro, during
treatment with Trastuzumab and other antitumor drugs [97].
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Conclusions:
- HER2 hot spot exons are not mutated in our patients of HER2 positive
metastatic breast cancer.
- PIK3CA gene is frequently mutated in HER2 positive metastatic breast
cancer patients in an Italian population.
- PIK3CA mutations on exons 9 and 20 affect patient’s survival, significantly.
Gaining PIK3CA mutations reduces patient’s overall survival as well as
progression free survival.
- Exon 4 of Akt1 gene is not frequently mutated in our patients. Only, 2 were
found in two patients.
- PTEN hot spot exons 5, 7 and 8 are frequently mutated in HER2 positive
metastatic breast cancer patients in an Italian population, but these mutations
do not affect patient’s survival.
- Homozygous V158V of FcγRIIIa or H131H of FcγRIIa polymorphisms
improve patient’s survival.
- Combination of PIK3CA/Akt1/PTEN mutational analysis and FcγRIIIa or
FcγRIIa polymorphisms could be a powerful tool in predicting patient’s
survival.
- IGF1R overexpression is related to patient’s response to Trastuzumab.
Complete response (RC) group has the lowest expression of IGF1R,
significantly.
- More studies are recommended to evaluate mentioned molecular factors in
predicting patient’s response to Trastuzumab and patient’s survival.
- New anti-tumor regimen combination could be used to overcome
Trastuzumab resistance,   for example, using PIK3CA/Akt/PTEN pathway or
IGF1R blockers, anti-VEGF and mTOR inhibitors could be new trials to treat
HER2 positive metastatic breast cancer.
- Circulating Tumor Cells CTC investigation might be the future tool in
patient’s classification by performing same molecular analysis.
- High Resolution Melting (HRM) technique is a powerful tool for SNPs
screening effectively.
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Appendix A:
Table of patients’ classes, survival and genotypes of screened genes.
RESPONSE I PFS II PFS OS PIK9 PIK20 Akt1 PTEN FcγRIIa FcγRIIIa
??? 7 NO 8.7 WT WT WT wt H/R V/V
NV 14 NO 34.8 WT WT WT wt H/R V/V
NV 13.8 3.3 22.7 WT WT L28F,T34T wt H/R V/V
NV
ITERROTTA
TP X FARE
TP DI BELLA
8.4 20.9 WT WT WT wt H/R F/V
PD 2.7 6.8 WT W1057X Y38Y V217I H/R F/V
PD 1.9 14.3 H554R WT WT wt H/R F/V
PD 3.8 2 6.2 WT WT WT wt H/R F/V
PD 1.3 1.7 22.5 WT WT WT wt H/R F/V
PD 3.3 5.8 20.5 WT D1018N WT V133I,
S113N
R/R F/V
PD 3.9 93.2 + WT WT WT wt H/R V/V
PD 2.8 6.9 13.6 WT WT WT Wt H/R V/V
RC 20.9 35.2 WT WT 15522C/T Wt H/R F/F
RC 20.5 40.1 + WT WT WT V216M H/R F/V
RC 10 1.5 25.6 WT WT WT Q110X H/R F/V
RC 14.3 11.4 37.4 WT WT WT wt H/R F/V
RC 48.7 2.5 51 WT WT WT wt H/R F/V
RC 23.4 5.2 62.1 WT WT WT wt H/R F/V
RC 12.4 54.2 WT WT WT wt R/R F/V
RC 40 47.5 WT WT V57V C105Y H/R V/V
RC 41 55 WT WT WT wt H/R V/V
RC 30.7 64.5 + WT WT WT wt H/R V/V
RC 16.4 15.4 48.9 + WT WT L28L,V45V wt H/R V/V
RC 9.5 4.7 56.3 WT WT WT wt H/R V/V
RC POST-CH 5.3 10.8 WT H1047R WT wt H/R F/V
RM 3.7 NO 4.7 E542K WT WT wt H/R V/V
RM 47.5 15.8 67.6 + WT WT WT Y225C R/R V/V
RP 32.5 54.1 WT WT T34T wt H/R F/F
RP 62.3 + 62.3 + WT WT WT P96L, R233* H/H F/V
RP 8.7 8.7 36.8 + WT H1047R WT P213S,R233* H/R F/V
RP 3 3.9 WT H1047L WT wt H/R F/V
RP 14.9 2.9 25.5 E542K WT WT wt H/R F/V
RP 11.2 14.1 E545K WT WT wt H/R F/V
RP 8.3 2.9 14.3 WT WT WT wt H/R F/V
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RP 11.9 10.4 32.4 WT WT WT wt H/R F/V
RP 5.7 10.9 WT WT WT wt H/R F/V
RP 19 + NO 19 + WT WT WT wt H/R F/V
RP 5.4 8.2 WT WT WT wt H/R F/V
RP 8.3 17.7 27.3 + WT WT WT wt H/R F/V
RP 3.9 5.1 + N515S WT WT wt R/R F/V
RP 18.2 1.6 31.5 WT WT WT wt R/R F/V
RP 12.9 2.8 23.8 WT WT WT wt R/R F/V
RP 10.5 7 30.7 WT WT WT wt R/R F/V
RP 5.1 12,3/
lapat
35.3 WT M1010I WT
R130*,
G230E
H/R F/V
RP 8 8.7 34.1 WT WT WT wt H/H V/V
RP 10.4 23.5 58.4 WT WT WT wt H/H V/V
RP 14.9 28.3 + WT WT WT wt H/R V/V
RP 11.2 6.4 35.5 WT WT WT wt H/R V/V
RP 8.8 13.8 122.8 WT WT WT wt H/R V/V
RP 12.4 3 20.9 WT D1056N WT wt R/R V/V
SD 8.7 24.4 WT WT WT Q214* H/H F/V
SD 4.1 5.8 13.7 WT WT WT C105Y H/R F/V
SD 4.9 5.3 22.6 WT WT WT H272R H/R F/V
SD 5.5 1.2 11.6 WT WT WT S227F,
E291K
H/R F/V
SD 10 2.7 17.7 WT H1047R WT Wt H/R F/V
SD 7.5 NO 9.8 E545K WT WT Wt H/R F/V
SD 15.4 24.2 + 39.6 + WT WT WT Wt H/R F/V
SD 34.9 22.17 61.5 WT WT WT Wt H/R F/V
SD 17.9 + 17.9 + WT WT WT Wt H/R F/V
SD 5.1 6.2 22 + WT WT WT Wt H/R F/V
SD 2.8 3.2 WT M1004I WT Wt R/R F/V
SD 9.1 11.6 26.7 WT WT WT Wt R/R F/V
SD 4.9 4.2 15.2 WT WT WT Wt R/R F/V
SD 3.7 5.7 22.1 WT WT WT Wt R/R F/V
SD 7.2 1.4 12.6 WT WT WT M134I H/R V/V
SD 14.8 6.9 61.5 WT WT WT wt H/R V/V
SD 24.2 13.3 58.7 + WT WT WT wt H/R V/V
SD 57.4 36 125.5 + WT WT WT wt R/R V/V
SD
INTERROTTA
TP X TOX
DOPO UN
MESE
9 9.6 WT WT R23Q wt H/R F/V
Wt Wt Wt Wt H/R F/V
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Wt Wt Wt Wt H/R F/V
Wt Wt Wt Wt H/R F/V
Wt Wt Wt Wt R/R F/V
Wt Wt Wt Wt R/R F/V
Wt Wt Wt Wt R/R F/V
E545K Wt Wt Wt H/R V/V
Wt Wt Wt Wt H/R V/V
Wt Wt ???? Wt H/R V/V
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Appendix B:
Histograms of reported mutations and polymorphisms in PIK3CA, AKT1,
PTEN and FcγRIIa genes.
I. PIK3CA mutations.
E542K (GAA> AAA)
542  wt (GAA)
E545K (GAG> AAG)
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545 wt (GAG)
H554R (CAC>CGC)
N515S (AAC>AGC)
72
FSM (5’ Intron 9)
M1004I (ATG>ATA)
M1010I (ATG>ATA)
73
D1018N (GAC>AAC)
D1018N (GAC>AAC)
1018 wt (GAC)
74
H1047L (CAT>TAT)
H1047R (CAT>CGT)
H1047R (CAT>CGT)
75
H1047R (CAT>CGT)
1047 wt (CAT)
W1057X (TGG>TAG)
76
D1056N (GAT>AAT)
1056 Wt (GAT)And 1957 wt (TGG)
II. Akt1 mutations.
R23Q (CGG>CAG)
L28F (CTC>CCT)
77
Y38Y (TAC>TAT)
L28L (CTC>CTT)
V45V (GTG>GTA)
78
R23Q (CGG>CAG)
L28F (CTC>CCT)
79
PTEN Mutations:
P96L (CCA>CTA)
M134I (ATG>ATA)
S227F (TCC>TTC)
V217I (GTC>ATC)
80
Y225C (TAT>TGT)
R233X (CGA>TGA)
E291K (GAA>AAA)
81
G127E (GGA>GAA)
K147R (AAG>AGG)
H272R (CAC>CCC)
82
C105Y (TGT>TAT)
Q110X (CAA>TAA)
V216M (GTG>ATG)
83
S113N (AGT>AAT)
V133I (GTA>ATA)
FcγIIRa (H131R)
84
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